Treatment Response and Survival in Methamphetamine‐Associated Pulmonary Arterial Hypertension
Among Meth-PAH patients treated with an aggressive parenteral prostacyclin strategy, there is not a large difference in mortality and treatment response to iPAH. Further research is warranted to explore the long-term effects of methamphetamine use on PAH pathogenesis and outcomes.
Authors
- Michael Insel
- C. Uhland (ORCID: https://orcid.org/0000-0003-2728-7294)
- Saad Kubba
- Franz Rischard (ORCID: https://orcid.org/0000-0002-6861-8304)
- Angela Gibbs
Institutions
- University of Arizona (US)
- Legacy Health (US)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1161/jaha.125.042673
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00